H
Hans-Peter Brunner-La Rocca
Researcher at Maastricht University Medical Centre
Publications - 271
Citations - 12025
Hans-Peter Brunner-La Rocca is an academic researcher from Maastricht University Medical Centre. The author has contributed to research in topics: Heart failure & Ejection fraction. The author has an hindex of 47, co-authored 243 publications receiving 9597 citations. Previous affiliations of Hans-Peter Brunner-La Rocca include University of Basel & University Hospital of Basel.
Papers
More filters
Journal ArticleDOI
Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents.
Matthias Pfisterer,Hans-Peter Brunner-La Rocca,Peter Buser,Peter Rickenbacher,Patrick Hunziker,Christian Mueller,Raban Jeger,Franziska Bader,Stefan Osswald,Christoph Kaiser,Basket-Late Investigators +10 more
TL;DR: After the discontinuation of clopidogrel, the benefit of DES in reducing target vessel revascularization is maintained but has to be balanced against an increase in late cardiac death or nonfatal MI, possibly related to late stent thrombosis.
Journal ArticleDOI
BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial.
Matthias Pfisterer,Peter Buser,Hans Rickli,Marc Gutmann,Paul Erne,Peter Rickenbacher,André Vuillomenet,Urs Jeker,Paul Dubach,Hansjürg Beer,Se-Il Yoon,Thomas M. Suter,Hans Osterhues,Michael M. Schieber,Patrick Hilti,Ruth Schindler,Hans-Peter Brunner-La Rocca +16 more
TL;DR: Heart failure therapy guided by N-terminal BNP did not improve overall clinical outcomes or quality of life compared with symptom-guided treatment, and patients' quality-of-life metrics improved over 18 months of follow-up.
Journal ArticleDOI
The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology
Wilfried Mullens,Kevin Damman,Veli-Pekka Harjola,Alexandre Mebazaa,Hans-Peter Brunner-La Rocca,Pieter Martens,Jeffrey M. Testani,W.H. Wilson Tang,Francesco Orso,Patrick Rossignol,Marco Metra,Gerasimos Filippatos,Gerasimos Filippatos,Petar M. Seferovic,Frank Ruschitzka,Andrew J.S. Coats +15 more
TL;DR: The manuscript addresses frequently encountered challenges, such as evaluation of congestion and clinical euvolaemia, assessment of diuretic response/resistance in the treatment of acute heart failure, and an approach towards stepped pharmacologic diUREtic strategies, based upon diuretics response.
Journal ArticleDOI
Effect of school based physical activity programme (KISS) on fitness and adiposity in primary schoolchildren: cluster randomised controlled trial.
Susi Kriemler,Lukas Zahner,Christian Schindler,Ursina Meyer,Tim Hartmann,Helge Hebestreit,Hans-Peter Brunner-La Rocca,Willem van Mechelen,Jardena J. Puder +8 more
TL;DR: A school based multi-component physical activity intervention including compulsory elements improved physical activity and fitness and reduced adiposity in children.
Journal ArticleDOI
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial
Iacopo Olivotto,Artur Oreziak,Roberto Barriales-Villa,Theodore P. Abraham,Ahmad Masri,Pablo García-Pavía,Pablo García-Pavía,Sara Saberi,Neal K. Lakdawala,Matthew T. Wheeler,Anjali T. Owens,Milos Kubanek,Wojciech Wojakowski,Morten Kvistholm Jensen,Juan Ramón Gimeno-Blanes,Kia Afshar,Jonathan Myers,Jonathan Myers,Sheila M. Hegde,Scott D. Solomon,Amy J. Sehnert,David Zhang,Wanying Li,Mondira Bhattacharya,Jay M. Edelberg,Cynthia Burstein Waldman,Steven J. Lester,Andrew Wang,Carolyn Y. Ho,Daniel Jacoby,Jozef Bartunek,Antoine Bondue,Emeline Van Craenenbroeck,David Zemanek,Morten Søndergaard Jensen,Jens Mogensen,Jens Jakob Thune,Philippe Charron,Albert Hagège,Olivier Lairez,Jean Noël Trochu,Christoph Axthelm,Hans Dirk Duengen,Norbert Frey,Veselin Mitrovic,Michael Preusch,Jeanette Schulz-Menger,Tim Seidler,Michael Arad,Majdi Halabi,Amos Katz,Daniel Monakier,Offir Paz,Samuel Viskin,Donna R. Zwas,Hans-Peter Brunner-La Rocca,Michelle Michels,Dariusz Dudek,Zofia Oko-Sarnowska,Nuno Cardim,Helder Pereira,Pablo García Pavia,Juan Ramon Gimeno Blanes,Rafael Hidalgo Urbano,Luis Miguel Rincón Diaz,Perry M. Elliott,Zaheer Yousef,Theodore Abraham,Paulino Alvarez,Richard G. Bach,Richard C. Becker,Lubna Choudhury,David Fermin,John L. Jefferies,Christopher M. Kramer,Neal K. Lakdawala,Steven Lester,Ali J. Marian,Mathew S. Maurer,Sherif F. Nagueh,David R. Owens,Florian Rader,Mark V. Sherrid,Jamshid Shirani,John Symanski,Aslan T. Turer,Omar Wever-Pinzon,Timothy C. Wong,Mohamad H. Yamani +88 more
TL;DR: Treatment with mavacamten improved exercise capacity, LVOT obstruction, NYHA functional class, and health status in patients with obstructive hypertrophic cardiomyopathy and highlights the benefits of disease-specific treatment for this condition.